Nkarta, Inc. Common Stock NKTX

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

• GlobeNewswire Inc. 8 sept

  Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

  Nkarta, Inc. announced selection for three scientific presentations at ACR Convergence 2026 in November, including two oral presentations on NKX019's safety profile and clinical activity in idiopathic inflammatory myopathy, and one poster presentation on systemic sclerosis. The company is advancing NKX019, an allogeneic CAR-NK cell therapy targeting CD19 in B-cell-mediated autoimmune diseases, with enrollment ongoing in the Ntrust Phase 1/2 clinical trials across multiple indications.

  

• GlobeNewswire Inc. 26 jun

  Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

  Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. The company reported ongoing enrollment in clinical trials at 4 billion cell dose levels and secured FDA agreement for outpatient dosing of NKX019, enabling treatment in community rheumatology centers and expanding patient access.